Wuhan Hvsen Biotechnology Co.,Ltd. (SHE:300871)

China flag China · Delayed Price · Currency is CNY
26.20
-1.28 (-4.66%)
Mar 2, 2026, 3:04 PM CST
132.27%
Market Cap 5.54B
Revenue (ttm) 1.67B
Net Income (ttm) 215.41M
Shares Out 201.58M
EPS (ttm) 1.19
PE Ratio 23.04
Forward PE 30.88
Dividend 0.20 (0.73%)
Ex-Dividend Date Aug 26, 2025
Volume 12,855,584
Average Volume 17,216,617
Open 26.96
Previous Close 27.48
Day's Range 25.99 - 27.17
52-Week Range 10.99 - 38.89
Beta 0.81
RSI 53.41
Earnings Date Apr 17, 2026

About Wuhan Hvsen Biotechnology

Wuhan Hvsen Biotechnology Co.,Ltd. engages in the research and development, and manufacture of macrolides APIs and preparations in China and internationally. The company offers tylvalosin tartrate powders and raw materials; florfenicol, cefquinome sulfate, and tildipirosin injections; and florfenicol powder/WSP, tylosin tartrate soluble powder, and tywasin premix products. It produces various veterinary drug products of raw materials and preparations, as well as traditional Chinese medicines extractives. Hvsen Biotechnology Co., Ltd. was founde... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2002
Employees 1,028
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 300871
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.